Drug development strategies for asthma: in search of a new paradigm

Patrick Holt, Peter Sly, F.D. Martinez, S.T. Weiss, B. Bjorksten, E. Von Mutius, U. Wahn

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

The spiraling costs of asthma treatment seem set to continue rising, given the equivocal performance of the latest generation of specific anti-inflammatory drugs in trials in adult asthmatics. We argue that the continuation of this trend is inevitable unless there is a substantial realignment of entrenched drug development policy in the pharmaceutical industry and a parallel shift in licensing policy by regulatory authorities to encourage the development of drugs capable of halting the progression from acute to chronic asthma when the disease first manifests in childhood. The theoretical framework for such an approach, including proof-of-principle data from studies in children with early-stage disease and a range of candidate drugs, already exists. What is needed is informed debate on the risks versus potential benefits of this approach.
Original languageEnglish
Pages (from-to)695-698
JournalNature Immunology
Volume5
DOIs
Publication statusPublished - 2004

Fingerprint Dive into the research topics of 'Drug development strategies for asthma: in search of a new paradigm'. Together they form a unique fingerprint.

Cite this